Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA.

Actoxumab (10 mg/kg) significantly inhibited cell rounding activity in Vero cells when treated with 2 ng/mL TcdA. [1]

Actoxumab-bezlotoxumab (0.1, 1 or 10 mg/kg) significantly protected mice in a dose-dependent manner from Clostridium difficile toxin attack models.
In acute and severe CDI models, Actoxumab-bezlotoxumab prevents inflammation and damage associated with TcdA and TcdB. [1]